Merck Eyes Primary Care Opportunities Despite Challenges
This article was originally published in The Pink Sheet Daily
Executive Summary
Two of Merck’s potential near-term launches, suvorexant for insomnia and odanacatib for osteoporosis, will enter crowded markets dominated by generics, but executives at the Citi Global Health Care conference maintain that novel mechanisms of action will address unmet market opportunities.
You may also be interested in...
Merck Loses Chance For Primary Care Blockbuster With Odanacatib Failure
Termination of osteoporosis drug odanacatib due to stroke risk means a loss for Merck in reliving the glory days of branded Fosamax.
Merck Insomnia Drug Shows Improvements; Filing On Track
Merck is confident it can compete in the highly generic insomnia market; Phase III results show the insomnia drug suvorexant may have further benefits for patients.
Merck Undeterred By Upcoming Singulair Loss; Focuses On Phase III
Merck reports second quarter earnings, looking past the patent expiration of Singulair to the drugs it icurrently is developing to replace the revenues it is expected to lose.